Table 3.
a. Subgroup analysis of the incidence of depression | ||||||
---|---|---|---|---|---|---|
Variable | k | Proportion | 95% CI | I2 | τ2 | p |
Gender | ||||||
Male | 30 | 0.32 | [0.26 ~ 0.39] | 100% | 0.0394 | p = 0 |
Female | 30 | 0.36 | [0.28 ~ 0.44] | 100% | 0.0564 | p = 0 |
Research period | ||||||
Early stage of COVID-19 outbreak (2019.12 ~ 2020.5) |
45 | 0.31 | [0.26 ~ 0.37] | 100% | 0.0403 | p = 0 |
The normalization stage of COVID-19 (2020.6 ~ Now) | 27 | 0.35 | [0.28 ~ 0.43] | 100% | 0.0452 | p = 0 |
Sample source region | ||||||
Eastern Asia | 52 | 0.27 | [0.23 ~ 0.32] | 100% | 0.0325 | p = 0 |
Western Asia | 4 | 0.46 | [0.35 ~ 0.57] | 96% | 0.0120 | p < 0.01 |
Southern Asia | 5 | 0.48 | [0.30 ~ 0.65] | 98% | 0.0406 | p < 0.01 |
Europe | 5 | 0.38 | [0.20 ~ 0.58] | 99.7% | 0.0507 | p < 0.01 |
North America | 3 | 0.34 | [0.21 ~ 0.48] | 99% | 0.0155 | p < 0.01 |
South America | 1 | 0.61 | [0.58 ~ 0.63] | NA | NA | NA |
Africa | 4 | 0.60 | [0.36 ~ 0.82] | 99% | 0.0618 | p < 0.01 |
Oceania | 1 | 0.48 | [0.44 ~ 0.52] | NA | NA | NA |
Educational stage | ||||||
Undergraduate and Postgraduate | 65 | 0.33 | [0.28 ~ 0.38] | 100% | 0.0429 | p = 0 |
Middle school | 9 | 0.28 | [0.20 ~ 0.35] | 100% | 0.0169 | p = 0 |
Major | ||||||
Medical | 29 | 0.33 | [0.26 ~ 0.40] | 100% | 0.0391 | p = 0 |
Non-medical | 30 | 0.39 | [0.33 ~ 0.45] | 100% | 0.0299 | p = 0 |
Evaluation tool | ||||||
PHQ-9 | 36 | 0.33 | [0.28 ~ 0.38] | 100% | 0.0279 | p = 0 |
SDS | 8 | 0.35 | [0.20 ~ 0.53] | 100% | 0.0673 | p = 0 |
DASS-21 | 16 | 0.37 | [0.26 ~ 0.49] | 100% | 0.0578 | p = 0 |
SCL-90 | 2 | 0.13 | [0.01 ~ 0.34] | 99% | 0.0325 | p < 0.01 |
HADS | 3 | 0.31 | [0.09 ~ 0.58] | 99% | 0.0640 | p < 0.01 |
Self-made scale | 4 | 0.25 | [0.18 ~ 0.33] | 95% | 0.0080 | p < 0.01 |
b. Subgroup analysis of the incidence of anxiety | ||||||
---|---|---|---|---|---|---|
Variable | k | Proportion | 95% CI | I2 | τ2 | p |
Gender | ||||||
Male | 37 | 0.24 | [0.19 ~ 0.29] | 100% | 0.0332 | p = 0 |
Female | 37 | 0.27 | [0.21 ~ 0.33] | 100% | 0.0423 | p = 0 |
Research period | ||||||
Early stage of COVID-19 outbreak (2019.12 ~ 2020.5) | 61 | 0.24 | [0.20 ~ 0.29] | 100% | 0.0401 | p = 0 |
The normalization stage of COVID-19 (2020.6 ~ Now) | 25 | 0.37 | [0.27 ~ 0.47] | 100% | 0.0674 | p = 0 |
Sample source region | ||||||
Eastern Asia | 64 | 0.22 | [0.18 ~ 0.26] | 100% | 0.0388 | p = 0 |
Western Asia | 4 | 0.44 | [0.35 ~ 0.54] | 94% | 0.0085 | p < 0.01 |
Southern Asia | 8 | 0.36 | [0.27 ~ 0.47] | 98% | 0.0222 | p < 0.01 |
Europe | 6 | 0.43 | [0.37 ~ 0.49] | 95% | 0.0064 | p < 0.01 |
North America | 3 | 0.35 | [0.30 ~ 0.40] | 91% | 0.0017 | p < 0.01 |
South America | 1 | 0.53 | [0.50 ~ 0.55] | NA | NA | NA |
Africa | 5 | 0.67 | [0.41 ~ 0.88] | 99% | 0.0855 | p < 0.01 |
Oceania | 1 | 0.37 | [0.33 ~ 0.41] | NA | NA | NA |
Educational stage | ||||||
Undergraduate and Postgraduate | 80 | 0.29 | [0.25 ~ 0.33] | 100% | 0.0487 | p = 0 |
Middle school | 9 | 0.25 | [0.12 ~ 0.40] | 100% | 0.0658 | p = 0 |
Primary school | 2 | 0.15 | [0.10 ~ 0.22] | 97% | 0.0036 | p < 0.01 |
Major | ||||||
Medical | 34 | 0.25 | [0.20 ~ 0.30] | 100 | 0.0307 | p = 0 |
Non-medical | 31 | 0.41 | [0.33 ~ 0.49] | 100 | 0.0491 | p = 0 |
Evaluation tool | ||||||
GAD-7 | 39 | 0.30 | [0.25 ~ 0.35] | 100% | 0.0291 | p = 0 |
SAS | 23 | 0.19 | [0.14 ~ 0.25] | 100% | 0.0302 | p = 0 |
DASS-21 | 17 | 0.42 | [0.31 ~ 0.54] | 100% | 0.0639 | p = 0 |
SCL-90 | 3 | 0.11 | [0.00 ~ 0.34] | 99% | 0.0621 | p < 0.01 |
HADS | 3 | 0.48 | [0.40 ~ 0.55] | 84% | 0.0038 | p < 0.01 |
Self-made scale | 5 | 0.23 | [0.03 ~ 0.56] | 100% | 0.1531 | p = 0 |
c. Subgroup analysis of the incidence of pressure | ||||||
---|---|---|---|---|---|---|
Variable | k | Proportion | 95% CI | I2 | τ2 | p |
Gender | ||||||
Male | 11 | 0.16 | [0.12 ~ 0.21] | 96% | 0.0090 | p < 0.01 |
Female | 11 | 0.19 | [0.12 ~ 0.28] | 99% | 0.0268 | p < 0.01 |
Research period | ||||||
Early stage of COVID-19 outbreak (2019.12 ~ 2020.5) | 15 | 0.29 | [0.17 ~ 0.43] | 100% | 0.0827 | p = 0 |
The normalization stage of COVID-19 (2020.6 ~ Now) | 14 | 0.35 | [0.25 ~ 0.47] | 100% | 0.0495 | p = 0 |
Sample source region | ||||||
Eastern Asia | 15 | 0.18 | [0.10 ~ 0.28] | 100% | 0.0504 | p = 0 |
Western Asia | 3 | 0.38 | [0.28 ~ 0.48] | 93% | 0.0079 | p < 0.01 |
Southern Asia | 2 | 0.52 | [0.33 ~ 0.71] | 96% | 0.0188 | p < 0.01 |
Europe | 3 | 0.47 | [0.32 ~ 0.62] | 99% | 0.0173 | p < 0.01 |
North America | 2 | 0.48 | [0.09 ~ 0.89] | 99% | 0.1093 | p < 0.01 |
South America | 1 | 0.58 | [0.55 ~ 0.60] | NA | NA | NA |
Africa | 3 | 0.52 | [0.24 ~ 0.79] | 99% | 0.0665 | p < 0.01 |
Oceania | 1 | 0.40 | [0.36 ~ 0.44] | NA | NA | NA |
Educational stage | ||||||
Undergraduate and Postgraduate | 28 | 0.31 | [0.22 ~ 0.40] | 100% | 0.0676 | p = 0 |
Middle school | 2 | 0.31 | [0.06 ~ 0.64] | 99% | 0.0583 | p < 0.01 |
Major | ||||||
Medical | 9 | 0.28 | [0.18 ~ 0.40] | 99% | 0.0349 | p < 0.01 |
Non-medical | 15 | 0.41 | [0.29 ~ 0.54] | 100% | 0.0661 | p = 0 |
Evaluation tool | ||||||
SRQ-20 | 2 | 0.60 | [0.18 ~ 0.94] | 100% | 0.1018 | p < 0.01 |
IES-6 | 2 | 0.21 | [0.03 ~ 0.49] | 100% | 0.0456 | p = 0 |
DASS-21 | 17 | 0.31 | [0.21 ~ 0.42] | 100% | 0.0584 | p = 0 |
SCL-90 | 2 | 0.19 | [0.11 ~ 0.29] | 96% | 0.0033 | p < 0.01 |
Self-made scale | 3 | 0.17 | [0.02 ~ 0.40] | 99% | 0.0536 | p < 0.01 |
d. Subgroup analysis of the incidence of fear | ||||||
---|---|---|---|---|---|---|
Variable | k | Proportion | 95% CI | I2 | τ2 | p |
Research period | ||||||
Early stage of COVID-19 outbreak (2019.12 ~ 2020.5) | 13 | 0.34 | [0.18 ~ 0.51] | 100% | 0.1084 | p = 0 |
The normalization stage of COVID-19 (2020.6 ~ Now) | 3 | 0.40 | [0.05 ~ 0.84] | 100% | 0.1730 | p = 0 |
Sample source region | ||||||
Eastern Asia | 13 | 0.24 | [0.12 ~ 0.39] | 100% | 0.0864 | p = 0 |
Western Asia | 2 | 0.70 | [0.31 ~ 0.96] | 100% | 0.0796 | p < 0.01 |
Europe | 2 | 0.64 | [0.61 ~ 0.67] | 0% | 0.0000 | p = 0.78 |